| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Dept of Internal Medicine, Pneumology, and 4 Institute of Pathology, University of Leipzig, Leipzig, 2 Max Delbrueck Centre for Molecular Medicine, Berlin-Buch, 3 Dept of Pneumology, Division of Internal Medicine, Charité-Universitätsmedizin Berlin, and 5 Institute of Pathology, University Hospital Charité, Humboldt University of Berlin, Berlin, Germany.
CORRESPONDENCE: C. Gessner, Dept of Internal Medicine, Pulmonary unit, Johannisallee 32, 04103, Germany. Fax: 49 3419712609. E-mail: gesc@medizin.uni-leipzig.de
Keywords: Molecular diagnosis, prognosis, survival, tumour staging, Y-box binding protein
Received: March 24, 2003
Accepted August 21, 2003
The human Y-box binding protein, YB-1, is a multifunctional protein that regulates gene expression. Nuclear expression of YB-1 has been associated with chemoresistance and poor prognosis of tumour patients.
Representative samples from autopsied material of primary tumours from 77 patients with NSCLC were investigated by immunohistochemistry for subcellular distribution of YB-1 and p53, in order to evaluate the prognostic role of nuclear expression of YB-1.
Cytoplasmic YB-1 expression was found in all tumour samples, whereas nuclear expression was only observed in 48%. There was no correlation with histological classification, clinical parameters or tumour size, stage and metastasis status. However, patients with positive nuclear YB-1 expression in tumours showed reduced survival times when compared with patients without nuclear expression. Including information about the histology and mutational status for p53 increased the prognostic value of nuclear YB-1. Patients with nuclear YB-1 expression and p53 mutations had the worst prognosis (median survival 3 months), while best outcome was found in patients with no nuclear YB-1 and wildtype p53 (median survival 15 months).
This suggests that the combined analysis of both markers allows a better identification of subgroups with varying prognosis. Nuclear expression of Y-box binding protien seems to be an independent prognostic marker.
This article has been cited by other articles:
|
|
 |
|
  S. M. Paranjape and E. Harris Y Box-binding Protein-1 Binds to the Dengue Virus 3'-Untranslated Region and Mediates Antiviral Effects J. Biol. Chem., October 19, 2007; 282(42): 30497 - 30508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bergmann, B. Royer-Pokora, E. Fietze, K. Jurchott, B. Hildebrandt, D. Trost, F. Leenders, J.-C. Claude, F. Theuring, R. Bargou, et al. YB-1 Provokes Breast Cancer through the Induction of Chromosomal Instability That Emerges from Mitotic Failure and Centrosome Amplification Cancer Res., May 15, 2005; 65(10): 4078 - 4087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Bader and P. K. Vogt Inhibition of Protein Synthesis by Y Box-Binding Protein 1 Blocks Oncogenic Cell Transformation Mol. Cell. Biol., March 15, 2005; 25(6): 2095 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Aljada, N. Ramnath, K. Donohue, S. Harvey, J. J. Brooks, S. M. Wiseman, T. Khoury, G. Loewen, H. K. Slocum, T. M. Anderson, et al. Upregulation of the Tissue Inhibitor of Metalloproteinase-1 Protein Is Associated With Progression of Human Non-Small-Cell Lung Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3218 - 3229. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
